Skip to main content

Advertisement

SpringerLink
Log in

Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The association of polymorphisms of tumor suppressor gene TP53 with breast cancer has widely been reported; however, the results are inconsistent. Here, we selected three commonly studied TP53 polymorphisms: codon 72 Arg > Pro, IVS3 16 bp Del/Ins, and IVS6 + 62A > G to explore their association with breast cancer risk by meta-analysis of published case–control studies. The results showed that codon 72 was not associated with breast cancer risk among 37 combined case–control studies (23,567 cases and 25,995 controls). However, a significant association with decreased risk of breast cancer was found in the Mediterranean studies (PP + PR vs. RR: OR = 0.32, 95% CI = 0.24−0.44, P < 0.001; PP vs. RR: OR = 0.35, 95% CI = 0.21−0.60, P < 0.001). IVS3 16 bp Del/Ins was significantly associated with an increased risk of developing breast cancer in a pooled 8 study dataset (2,470 cases and 2,825 controls; Ins/Ins + Del/Ins vs. Del/Del: OR = 1.15, 95% CI = 1.01−1.30, P = 0.04; Ins/Ins vs. Del/Del: OR = 1.75, 95% CI = 1.20−2.37, P = 0.003). No significant association was observed between IVS6 + 62A > G and breast cancer risk in a total of 10 studies (8,537 cases and 9,586 controls). These results suggest that IVS3 16 bp Del/Ins is likely an important genetic marker contributing to susceptibility of breast cancer, and codon 72 has a potential role in association with breast cancer risk within certain populations or regions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310. doi:10.1038/35042675

    Article  CAS  PubMed  Google Scholar 

  2. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275–283. doi:10.1038/nrm2147

    Article  CAS  PubMed  Google Scholar 

  3. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 2:95–107. doi:10.1038/nrc2584

    Article  CAS  Google Scholar 

  4. Pietsch EC, Humbey O, Murphy ME (2006) Polymorphisms in the p53 pathway. Oncogene 25:1602–1611. doi:10.1038/sj.onc.1209367

    Article  CAS  PubMed  Google Scholar 

  5. Hrstka R, Coates PJ, Vojtesek B (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13:440–453. doi:10.1111/j.1582-4934.2008.00634.x

    Article  CAS  PubMed  Google Scholar 

  6. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887–898. doi:10.1038/sj.onc.1201263

    Article  CAS  PubMed  Google Scholar 

  7. Dumont P, Leu JI, Della Pietra ACIII, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365. doi:10.1038/ng1093

    Article  CAS  PubMed  Google Scholar 

  8. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199. doi:10.1002/ijc.11548

    Article  CAS  PubMed  Google Scholar 

  9. Salvioli S, Bonafé M, Barbi C, Storci G, Trapassi C, Tocco F, Gravina S, Rossi M, Tiberi L, Mondello C, Monti D, Franceschi C (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4:1264–1271

    CAS  PubMed  Google Scholar 

  10. Siddique M, Sabapathy K (2006) Trp53-dependent DNA repair is affected by the codon 72 polymorphism. Oncogene 25:3489–3500. doi:10.1038/sj.onc.1209405

    Article  CAS  PubMed  Google Scholar 

  11. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y (2009) A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: Evidence from 15,857 subjects. Lung Cancer(ahead of print) doi: 10.1016/j.lungcan.2008.12.009

  12. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121:1481–1486. doi:10.1002/ijc.22833

    Article  CAS  PubMed  Google Scholar 

  13. Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS (2004) Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 85:301–308. doi:10.1016/j.ijgo.2003.08.017

    Article  CAS  PubMed  Google Scholar 

  14. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32. doi:10.1186/1471-2407-8-32

    Article  PubMed  CAS  Google Scholar 

  15. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956. doi:10.1038/sj.onc.1207305

    Article  CAS  PubMed  Google Scholar 

  16. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13:5974–5981. doi:10.1158/1078-0432.CCR-07-0113

    Article  CAS  PubMed  Google Scholar 

  17. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316

    Article  CAS  PubMed  Google Scholar 

  18. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112

    CAS  PubMed  Google Scholar 

  19. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269–272

    Article  CAS  PubMed  Google Scholar 

  20. Buyru N, Altinisik J, Demokan S, Dalay N (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207–213. doi:10.1016/j.cdp.2007.04.004

    Article  CAS  PubMed  Google Scholar 

  21. Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57. doi:10.1016/j.annepidem.2007.06.006

    Article  PubMed  Google Scholar 

  22. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grünewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90:1989–1994. doi:10.1038/sj.bjc.6601779

    Article  CAS  PubMed  Google Scholar 

  23. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144–1148. doi:10.1038/sj.bjc.6602451

    Article  CAS  PubMed  Google Scholar 

  24. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van’t Veer LJ, Breast Cancer Association Consortium (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? a large pooled series from the breast cancer association consortium. Cancer Res 67:9584–9590. doi:10.1158/0008-5472.CAN-07-0738

    Article  CAS  PubMed  Google Scholar 

  25. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case–control study. Carcinogenesis 28:1680–1686. doi:10.1093/carcin/bgm097

    Article  CAS  PubMed  Google Scholar 

  26. The Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the breast cancer association consortium. J Natl Cancer Inst 98:1382–1396. doi:10.1093/jnci/djj374

    Article  Google Scholar 

  27. American Cancer Society (2007) Global cancer facts and Figs 2007. American Cancer Society Inc, USA

    Google Scholar 

  28. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, Wei Q (2007) Polymorphic T53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 13:4300–4305. doi:10.1158/1078-0432.CCR-07-0469

    Article  CAS  PubMed  Google Scholar 

  29. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203. doi:10.1016/j.canlet.2004.03.031

    Article  CAS  PubMed  Google Scholar 

  30. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy N (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87. doi:10.1007/s10549-007-9821-3

    Article  CAS  PubMed  Google Scholar 

  31. Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 Codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–392. doi:10.1006/mcbr.2000.0241

    Article  CAS  PubMed  Google Scholar 

  32. Garcia-Closas M, Kristensen V, Langerod A, Qi Y, Yeager M, Burdett L, Welch R, Lissowska J, Peplonska B, Brinton L, Gerhard DS, Gram IT, Perou CM, Borresen-Dale AL, Chanock S (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121:2532–2538. doi:10.1002/ijc.22985

    Article  CAS  PubMed  Google Scholar 

  33. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM, SEARCH breast cancer study (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27. doi:10.1186/bcr1669

    Article  PubMed  CAS  Google Scholar 

  34. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089

    Article  CAS  PubMed  Google Scholar 

  35. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C 14-to-A4T14 at Exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast cancer 10(4):307–311

    Article  PubMed  Google Scholar 

  36. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA, Das BC (2003) Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252:117–124

    Article  CAS  PubMed  Google Scholar 

  37. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14:2245–2252. doi:10.1158/1055-9965.EPI-05-0153

    Article  CAS  PubMed  Google Scholar 

  38. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q, Shen H (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766–771. doi:10.1093/carcin/bgi295

    Article  CAS  PubMed  Google Scholar 

  39. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38–42. doi:10.1016/j.cancergencyto.2006.09.010

    Article  CAS  PubMed  Google Scholar 

  40. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN (2007) Implication of BRCA2 -26G > A 5’ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res 9:R71. doi:10.1186/bcr1780

    Article  PubMed  CAS  Google Scholar 

  41. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K (2008) MDM2 SNP309 G allele increases risk but the Tallele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754–761. doi:10.1093/carcin/bgn024

    Article  CAS  PubMed  Google Scholar 

  42. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764–770

    Article  CAS  PubMed  Google Scholar 

  43. Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN (2003) Evidence against involvement of P53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433. doi:10.1002/ijc.10834

    Article  CAS  PubMed  Google Scholar 

  44. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65. doi:10.1016/j.canlet.2004.11.025

    Article  CAS  PubMed  Google Scholar 

  45. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103. doi:10.1158/1078-0432.CCR-05-0173

    Article  CAS  PubMed  Google Scholar 

  46. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057. doi:10.1093/hmg/ddm050

    Article  CAS  PubMed  Google Scholar 

  47. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96. doi:10.1186/1471-2407-8-96

    Article  PubMed  CAS  Google Scholar 

  48. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control 18:621–625. doi:10.1007/s10552-007-9004-x

    Article  PubMed  Google Scholar 

  49. Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 108:93–99. doi:10.1007/s10549-007-9573-0

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded in part by Program of Introducing Talents of Discipline to Universities (Grant No. B08029) and a grant 2009DFA31940 from The Ministry of Science and Technology.

Author information

Authors and Affiliations

  1. Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, 430074, Wuhan, China

    Zheng Hu, Xiang Li & Li Su

  2. Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China

    Rong Yuan

  3. Department of Research and Development, Applied Genomics Inc, Burlingame, CA, USA

    Brian Z. Ring

Authors
  1. Zheng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rong Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian Z. Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Su.

Additional information

Zheng Hu and Xiang Li contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 225 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, Z., Li, X., Yuan, R. et al. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120, 705–714 (2010). https://doi.org/10.1007/s10549-009-0488-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0488-9

Keywords

Search

Navigation